Lung Cancer: Targets and Therapy
Volume 15, 2024 - Issue
Open access
594
Views
0
CrossRef citations to date
0
Altmetric
COMMENTARY
MARIPOSA: Can Amivantamab and Lazertinib Replace Osimertinib in the Front-Line Setting?
Danielle Brazel1 Department of Hematology/Oncology, Scripps Clinic/Scripps Green Hospital, La Jolla, CA, USAView further author information
& Misako Nagasaka2 Department of Hematology/Oncology, University of California Irvine School of Medicine, Chao Family Cancer Center, Orange, CA, USA;3 Department of Medicine, St. Marianna University School of Medicine, Kawasaki, JapanCorrespondence[email protected]
https://orcid.org/0000-0001-5308-615XView further author information
Pages 41-47
|
Received 08 Dec 2023, Accepted 19 Mar 2024, Published online: 12 Apr 2024
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.